Chengdu Easton Biopharmaceuticals Co., Ltd. (SHA:688513)

Market Cap	9.25B +59.8%
Revenue (ttm)	1.35B +0.9%
Net Income	274.30M +22.6%
EPS	1.58 +24.4%
Shares Out	174.35M
PE Ratio	33.58
Forward PE	30.51
Dividend	0.49 (0.92%)
Ex-Dividend Date	Jun 2, 2026

Volume	1,981,638
Open	54.01
Previous Close	53.08
Day's Range	48.86 - 54.91
52-Week Range	37.50 - 80.48
Beta	0.11
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 18, 2026

About SHA:688513

Chengdu Easton Biopharmaceuticals Co., Ltd., together with its subsidiaries, engages in the research, development, manufacture, and commercialization of pharmaceutical products. The company provides finished dosage forms comprising capsules, tablets, and injections, as well as active pharmaceutical ingredients (API). It also offers API products, such as Apixaban for cardiovascular applications; Apualutamide, Bosutinib, Dacomitinib, Ibrutinib, Nilotinib HCL, Nintedanib, Relugolix, and Ruxolitinib Phosphate for oncological applications; Bricarace...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2009
• Employees: 1,480
• Stock Exchange: Shanghai Stock Exchange
• Ticker Symbol: 688513

Financial Performance

In 2025, SHA:688513's revenue was 1.33 billion, a decrease of -1.36% compared to the previous year's 1.35 billion. Earnings were 284.06 million, an increase of 19.24%.